Search Results

Inhibikase Therapeutics, Inc. today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs.

Inhibikase Therapeutics, Inc. today announced the company has completed enrollment in the Phase 2 ‘201’ trial evaluating the safety and tolerability of risvodetinib (“risvo”).

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments.

Inhibikase Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments.

Inhibikase Therapeutics, Inc. announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration for IkT-001Pro as a candidate treatment for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics, Inc. today issued a Letter to Shareholders.

Inhibikase Therapeutics, Inc. announced that the Company will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the U.S. Food and Drug Administration for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial evaluating risvodetinib (“risvo”) at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal.

Inhibikase Therapeutics, Inc. today announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024.